NGM Biopharmaceuticals
Edit

NGM Biopharmaceuticals

http://www.ngmbio.com/
Tags:DevelopmentDrugEngineeringHealthTechHumanInterestMarketMedTechPlatformResearch
We are a clinical stage biopharmaceutical company advancing a robust pipeline of drug candidates to address a spectrum of large, unmet medical needs. We are focused on harnessing powerful, untapped biology underlying major diseases to develop transformative therapeutics for patients. Our initial R&D focus has been to develop a portfolio of high-impact therapeutics for the underserved patient populations who suffer from cardio-metabolic and liver diseases. We believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of other disease areas as well, such as cancer. NGM Bio’s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. As we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. Coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles. All of NGM Bio’s clinical candidates are first-in-class therapies and several are modulating targets or pathways that were first identified by NGM Bio.
Location: United States, California, South San Francisco
Member count: 201-500
Total raised: $101M
Founded date: 2008

Investors 4

Funding Rounds 2

DateSeriesAmountInvestorsDeal News
18.07.2013Series C$50M-vcnewsdail...
15.03.2010Series B$51M-finsmes.co...

Mentions in press and media 40

DateTitleDescriptionCategoryAuthorSource
04.11.2022NGM Bio An.../EIN News/ -- --Poster present...--einpresswi...
17.10.2022NGM Bio’s ...After NGM Biopharmaceuticals’ ...--medcitynew...
17.10.2022NGM Bio An...Trial did not meet primary end...--globenewsw...
16.10.2022NGM Bio to...SOUTH SAN FRANCISCO, Calif., O...--globenewsw...
13.09.2022NGM Bio Pr...NGM120 is a novel antagonist a...--globenewsw...
06.09.2022NGM Bio Pr...NGM120 is a novel antagonist a...--globenewsw...
15.08.2022NGM Bio An...Poster presentation at upcomin...--globenewsw...
04.08.2022NGM Bio Pr...--Initiated Phase 1/1b clinica...--globenewsw...
30.06.2022NGM Bio Ap...-- William J. Rieflin to trans...--globenewsw...
23.06.2022NGM Bio to...--NGM621, a monoclonal antibod...--globenewsw...
Show more